WO2007039155A3 - Verwendung von aktivatoren der löslichen guanylatzyklase zur behandlung von akuten und chronischen lungenkrankheiten - Google Patents

Verwendung von aktivatoren der löslichen guanylatzyklase zur behandlung von akuten und chronischen lungenkrankheiten Download PDF

Info

Publication number
WO2007039155A3
WO2007039155A3 PCT/EP2006/009264 EP2006009264W WO2007039155A3 WO 2007039155 A3 WO2007039155 A3 WO 2007039155A3 EP 2006009264 W EP2006009264 W EP 2006009264W WO 2007039155 A3 WO2007039155 A3 WO 2007039155A3
Authority
WO
WIPO (PCT)
Prior art keywords
lung diseases
chronic lung
treating acute
guanylate cyclase
soluble guanylate
Prior art date
Application number
PCT/EP2006/009264
Other languages
English (en)
French (fr)
Other versions
WO2007039155A2 (de
Inventor
Thomas Krahn
Johannes-Peter Stasch
Gerrit Weimann
Wolfgang Thielemann
Original Assignee
Bayer Healthcare Ag
Thomas Krahn
Johannes-Peter Stasch
Gerrit Weimann
Wolfgang Thielemann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Thomas Krahn, Johannes-Peter Stasch, Gerrit Weimann, Wolfgang Thielemann filed Critical Bayer Healthcare Ag
Priority to CA002624716A priority Critical patent/CA2624716A1/en
Priority to AU2006299149A priority patent/AU2006299149A1/en
Priority to US12/083,121 priority patent/US20090286781A1/en
Priority to JP2008533900A priority patent/JP2009510142A/ja
Priority to BRPI0616921-0A priority patent/BRPI0616921A2/pt
Priority to EP06777198A priority patent/EP1945218A2/de
Publication of WO2007039155A2 publication Critical patent/WO2007039155A2/de
Publication of WO2007039155A3 publication Critical patent/WO2007039155A3/de
Priority to IL190619A priority patent/IL190619A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung von Verbindungen der Formeln I-VI zur Herstellung eines Arzneimittels zur Behandlung von akuten und chronischen Lungenkrankheiten wie den Respiratory Distress Syndromen [acute lung injury (ALI), acute respiratory distress syndrome (ARDS)] und der Behandlung der COPD.
PCT/EP2006/009264 2005-10-06 2006-09-23 Verwendung von aktivatoren der löslichen guanylatzyklase zur behandlung von akuten und chronischen lungenkrankheiten WO2007039155A2 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002624716A CA2624716A1 (en) 2005-10-06 2006-09-23 Use of soluble guanylate cyclase activators for treating acute and chronic lung diseases
AU2006299149A AU2006299149A1 (en) 2005-10-06 2006-09-23 Use of soluble guanylate cyclase activators for treating acute and chronic lung diseases
US12/083,121 US20090286781A1 (en) 2005-10-06 2006-09-23 Use of Suluble Guanylate Cyclase Acitvators for Treating Acute and Chronic Lung Diseases
JP2008533900A JP2009510142A (ja) 2005-10-06 2006-09-23 急性および慢性肺障害の処置のための可溶性グアニル酸シクラーゼ活性化剤の使用
BRPI0616921-0A BRPI0616921A2 (pt) 2005-10-06 2006-09-23 aplicação de ativadores da guanilato ciclase solúvel para o tratamento de doenças pulmonares agudas e crÈnicas
EP06777198A EP1945218A2 (de) 2005-10-06 2006-09-23 Verwendung von aktivatoren der löslichen guanylatzyklase zur behandlung von akuten und chronischen lungenkrankheiten
IL190619A IL190619A0 (en) 2005-10-06 2008-04-03 Use of soluble guanylate cyclase activators for treating acute and chronic lung diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005047946.4 2005-10-06
DE102005047946A DE102005047946A1 (de) 2005-10-06 2005-10-06 Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten

Publications (2)

Publication Number Publication Date
WO2007039155A2 WO2007039155A2 (de) 2007-04-12
WO2007039155A3 true WO2007039155A3 (de) 2007-10-11

Family

ID=37106347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/009264 WO2007039155A2 (de) 2005-10-06 2006-09-23 Verwendung von aktivatoren der löslichen guanylatzyklase zur behandlung von akuten und chronischen lungenkrankheiten

Country Status (13)

Country Link
US (1) US20090286781A1 (de)
EP (1) EP1945218A2 (de)
JP (1) JP2009510142A (de)
KR (1) KR20080065283A (de)
CN (1) CN101282727A (de)
AU (1) AU2006299149A1 (de)
BR (1) BRPI0616921A2 (de)
CA (1) CA2624716A1 (de)
DE (1) DE102005047946A1 (de)
IL (1) IL190619A0 (de)
RU (1) RU2417083C2 (de)
WO (1) WO2007039155A2 (de)
ZA (1) ZA200802874B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202008014557U1 (de) 2008-10-27 2009-03-12 Eberhard-Karls-Universität Tübingen Universitätsklinikum Therapeutische Verwendung
SI2531187T1 (sl) * 2010-02-05 2016-01-29 Adverio Pharma Gmbh Stimulatorji sGC ali aktivatorji sGC sami in v kombinaciji z inhibitorji PDE5 za zdravljenje cistične fibroze
US20130158028A1 (en) * 2010-06-25 2013-06-20 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
CN102485724B (zh) * 2010-12-06 2015-08-12 中国人民解放军军事医学科学院毒物药物研究所 取代噻吩基吡唑并吡啶类化合物及其医药用途
US9090610B2 (en) * 2011-04-21 2015-07-28 Bayer Intellectual Property Gmbh Fluoroalkyl-substituted pyrazolopyridines and use thereof
EP2875003B1 (de) * 2012-07-20 2016-11-16 Bayer Pharma Aktiengesellschaft Neue 5-aminotetrahydrochinolin-2-carbonsäuren und ihre verwendung
EP3024455A1 (de) 2013-07-25 2016-06-01 Bayer Pharma Aktiengesellschaft Sgc-stimulatoren oder sgc-aktivatoren und pde5-inhibitoren in kombination mit einer zusatzbehandlung zur behandlung von zystischer fibrose
CN108785309A (zh) * 2018-04-23 2018-11-13 周静 化合物在制备治疗慢性肺病的药物中的用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2395431A (en) * 2002-11-20 2004-05-26 Northwick Park Inst For Medica Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide
WO2005013691A1 (en) * 2003-08-04 2005-02-17 Hemocorm Limited Use of boranocarbonates for the therapeutic delivery of carbon monoxide
US20050089473A1 (en) * 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
WO2005042022A2 (en) * 2003-10-29 2005-05-12 Pfizer Limited Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist
WO2005077005A2 (en) * 2004-02-04 2005-08-25 The General Hospital Corporation Enhancing the effectiveness of an inhaled therapeutic gas
WO2006037491A1 (en) * 2004-10-05 2006-04-13 Bayer Healthcare Ag A guanylane cyclase stimulator and nitric oxide for treating bronchoconstriction and pulmonary vasoconstriction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) * 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2003090870A1 (en) * 2002-04-26 2003-11-06 Altana Pharma Ag Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10351903A1 (de) * 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2395431A (en) * 2002-11-20 2004-05-26 Northwick Park Inst For Medica Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide
WO2005013691A1 (en) * 2003-08-04 2005-02-17 Hemocorm Limited Use of boranocarbonates for the therapeutic delivery of carbon monoxide
US20050089473A1 (en) * 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
WO2005042022A2 (en) * 2003-10-29 2005-05-12 Pfizer Limited Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist
WO2005077005A2 (en) * 2004-02-04 2005-08-25 The General Hospital Corporation Enhancing the effectiveness of an inhaled therapeutic gas
WO2006037491A1 (en) * 2004-10-05 2006-04-13 Bayer Healthcare Ag A guanylane cyclase stimulator and nitric oxide for treating bronchoconstriction and pulmonary vasoconstriction

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOGGRELL S A: "CLINICAL POTENTIAL OF NITRIC OXIDE-INDEPENDENT SOLUBLE GUANYLATE CYCLASE ACTIVATORS", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol. 6, no. 9, 2005, pages 874 - 878, XP008068884, ISSN: 1472-4472 *
STASCH J-P ET AL: "NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 136, no. 5, 2002, pages 773 - 783, XP002403267, ISSN: 0007-1188 *
STASCH, JOHANNES-PETER ET AL: "Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels", JOURNAL OF CLINICAL INVESTIGATION , 116(9), 2552-2561 CODEN: JCINAO; ISSN: 0021-9738, 2006, XP008079104 *

Also Published As

Publication number Publication date
ZA200802874B (en) 2009-09-30
KR20080065283A (ko) 2008-07-11
IL190619A0 (en) 2008-12-29
DE102005047946A1 (de) 2007-05-03
CN101282727A (zh) 2008-10-08
EP1945218A2 (de) 2008-07-23
RU2417083C2 (ru) 2011-04-27
WO2007039155A2 (de) 2007-04-12
CA2624716A1 (en) 2007-04-12
JP2009510142A (ja) 2009-03-12
BRPI0616921A2 (pt) 2011-07-05
RU2008117303A (ru) 2009-11-20
AU2006299149A1 (en) 2007-04-12
US20090286781A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
WO2007039155A3 (de) Verwendung von aktivatoren der löslichen guanylatzyklase zur behandlung von akuten und chronischen lungenkrankheiten
WO2006117300A3 (en) Crystalline forms of tiotropium bromide
WO2006117299A3 (en) Novel crystalline forms of tiotropium bromide
WO2007103105A3 (en) Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
WO2007015017A3 (fr) Nouveaux derives de polyquinoleines et leur utilisation therapeutique
IL177043A0 (en) Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2005121078A3 (de) Substituierte cyclopenten-verbindungen
WO2007148208A3 (en) Carbonylated (aza) cyclohexanes as dopamine d3 receptor ligands
WO2007045462A3 (de) Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln
IL179758A0 (en) Substituted tetrahydro - 2h - isoquinolin - 1 - one derivatives, method for the production thereof, and use of the same as medicaments
WO2007003962A3 (en) Gpcr agonists
JO2756B1 (en) The second preparation of aqueous pyrimidnon containing 4- (4-ciano-2-2 thiourail) and its use)
WO2008145681A3 (en) Ccr2 receptor antagonists and uses thereof
WO2011158042A3 (en) Ureido- pyrazole derivatives for use in the treatment of rhinovirus infections
WO2007066017A3 (fr) Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament
ZA200610640B (en) Heteroaryl compounds for use as betamimetics in the treatment of respiratory diseases
WO2007000325A3 (de) Substituierte 1-oxa-3,8-diazaspiro[4.5]-decan-2-on-verbindungen und deren verwendung zur herstellung von arzneimitteln
IL187235A0 (en) 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
ZA200803200B (en) Process for reducing the formaldehyde content of a gas
WO2008011113A3 (en) Thiadiazolidinone derivatives
HK1116095A1 (en) A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma.
HK1110782A1 (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroqe inoline derivatives as medicaments for the treatment of infertility
WO2006128847A3 (en) Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
MY140538A (en) Substituted n-acyl-2-aminothiazoles

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680037389.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006777198

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2616/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/004408

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2624716

Country of ref document: CA

Ref document number: 190619

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008533900

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006299149

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087010682

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008117303

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2006299149

Country of ref document: AU

Date of ref document: 20060923

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006299149

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006777198

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12083121

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0616921

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080404